Search clinical trials for: AZD2066

Total 100 results

AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066 (PET)

Healthy

Sweden
AstraZeneca
Quintiles, Inc.

Terminated

AZD2066 Neuropathic Pain - Mechanical Hypersensitivity (NP-MH)

Neuropathic Pain | Mechanical Hypersensitivity

United States
AstraZeneca

Completed

AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers

Healthy
AstraZeneca

Completed

Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066

Pain

United Kingdom
AstraZeneca

Completed

Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

Pain | Diabetic Neuropathy

United States
AstraZeneca

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects

Pain

Sweden
AstraZeneca

Completed

14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations

Reflux Episodes

Netherlands
AstraZeneca

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics After Multiple Doses of AZD2066 in Japanese Subjects

Healthy

Japan
AstraZeneca

Completed

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

Reflux

Netherlands, Belgium
Samsung Medical Center

Withdrawn

Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy (TSC1/2_SC)

Solid Tumor

Korea, Republic of
AstraZeneca

Completed

A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (CIRRUS)

Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD) | Laymen Terminology Chronic Bronchitis and Emphysema

Bulgaria, Germany, Hungary, Ukraine
Massachusetts General Hospital
United States Department of Defense; AstraZeneca

Completed

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Meningioma | Neurofibromatosis 2

United States
AstraZeneca
Quintiles, Inc.

Completed

This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral Dose

Chronic Obstructive Pulmonary Disease

United Kingdom
AstraZeneca

Completed

AZD9056 Relative Bioavailability Study

Healthy

United Kingdom
AstraZeneca

Terminated

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Lymphoma | Multiple Myeloma | Advanced Solid Tumors | Hematologic Malignancies

United States
AstraZeneca

Completed

Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069

Asthma

Germany
AstraZeneca

Completed

An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516

Healthy

Sweden
Massachusetts General Hospital
National Cancer Institute (NCI); AstraZeneca

Active, not recruiting

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Meningioma

United States
Samsung Medical Center
AstraZeneca

Terminated

Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification ([SUKSES-D])

Small Cell Lung Cancer

Korea, Republic of
AstraZeneca

Completed

Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis (STRATUS)

Bronchiectasis | Lung Disease | Respiratory Diseases

Czech Republic, United Kingdom, Poland
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Ascending Doses of AZD5069 in Healthy Volunteers

Healthy

United Kingdom
AstraZeneca

Completed

Open Label, Healthy Volunteers, ADME Study With Single Oral Administration of [14C] AZD5069

Healthy

United Kingdom
AstraZeneca

Completed

Japanese Single and Multiple Ascending Dose (JSMAD), Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of AZD5069 (JSMAD)

Healthy

United Kingdom
AstraZeneca
Quintiles, Inc.

Completed

To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers

Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years. | Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80

United Kingdom
AstraZeneca

Active, not recruiting

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

Non-alcoholic Steatohepatitis (NASH)

United States
AstraZeneca

Completed

A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma. (NIMBUS)

Asthma

Bulgaria, Czech Republic, Mexico, Poland, Russian Federation, South Africa, United Kingdom, Germany, Romania, Ukraine, Canada, Hungary, Slovakia
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects

Healthy

Japan
AstraZeneca

Completed

AZD8566 Food Effect/Microtracer Study

Healthy Volunteer Study

United Kingdom
Samsung Medical Center

Withdrawn

Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy (RICTOR_SC)

Solid Tumor

Korea, Republic of
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069

Chronic Obstructive Pulmonary Disease (COPD).

United Kingdom
Institute of Cancer Research, United Kingdom
AstraZeneca; Astellas Pharma Inc; Prostate Cancer UK

Terminated

Combination Study of AZD5069 and Enzalutamide. (ACE)

Metastatic Castration Resistant Prostate Cancer

United Kingdom, Switzerland
AstraZeneca

Withdrawn

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (INHIBITOR)

Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
Royal Marsden NHS Foundation Trust
AstraZeneca; Institute of Cancer Research, United Kingdom

Completed

A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel. (TAX-TORC)

Advanced Cancer

United Kingdom
AstraZeneca

Completed

An Open-Label, Dose-Escalation Study of AZD2461

Refractory Solid Tumors | Cancer Tumor

United States
AstraZeneca

Recruiting

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)

Non-Small-Cell Lung Carcinoma

China, Korea, Republic of, Spain, United States, Belgium, Netherlands, Malaysia, Taiwan, France, Brazil, Thailand, Japan, Singapore, Denmark, Moldova, Republic of, United Kingdom, Georgia, Australia
Canadian Cancer Trials Group
AstraZeneca

Completed

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

Glioblastoma Multiforme

Canada
AstraZeneca

Completed

Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056

Rheumatoid Arthritis

United Kingdom
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of AZD8566.

Pharmacokinetics

United Kingdom
AstraZeneca

Active, not recruiting

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
AstraZeneca

Terminated

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Spain, United States, Korea, Republic of, France, Portugal, Australia, Italy
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Activity of AZD5069 When Given as a Single Dose to Healthy Male and/or Female Subjects

Healthy

United Kingdom
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers

Healthy

Sweden
AstraZeneca

Completed

Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of AZD8566.

Healthy Volunteer

United Kingdom
AstraZeneca

Completed

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.

T2DM With NAFLD
Samsung Medical Center

Terminated

Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy

Cancer of Stomach

Korea, Republic of
Samsung Medical Center

Terminated

Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy (AZD2014)

Stomach Neoplasms

Korea, Republic of
AstraZeneca

Completed

AZD5069 Neutrophil Function Study

Chemokine Receptor 2 (CXCR2) Antagonist

United Kingdom
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca

Completed

Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer (CaNCaP02)

Prostate Cancer

United Kingdom
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
AstraZeneca

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

Advanced Solid Malignancies

United Kingdom

3

Subscribe